These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 19264155

  • 21. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
    Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-tung S, Rajatanavin R.
    J Bone Miner Metab; 2003; 21(6):421-7. PubMed ID: 14586800
    [Abstract] [Full Text] [Related]

  • 22. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.
    Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR.
    J Bone Miner Res; 2007 Apr; 22(4):503-8. PubMed ID: 17243862
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [Abstract] [Full Text] [Related]

  • 28. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [Abstract] [Full Text] [Related]

  • 29. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
    Uemura Y, Sone T, Tanaka S, Miyazaki T, Tsukiyama M, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) Research Group.
    Curr Med Res Opin; 2020 Nov; 36(11):1847-1859. PubMed ID: 32870712
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
    Masaryk P, Stancíková M, Letkovská A, Rovenský J.
    Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Osteoporosis and bisphosphonates].
    Zuber MA.
    Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.
    Mersereau JE, Khouri C, Jaffe RB.
    Fertil Steril; 2010 Aug; 94(3):1138-40. PubMed ID: 20056199
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.